XXVIIIe congrès du CREGG, 25–26 septembre 2009, Marne-la-Vallée

Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69:491–497. Mateus C, ESMO 2006. Hébuterne X. Effets des cancers sur l’état nutritionnel et la prise alimentaire: perception des maladies. Nutr Clin Métabol 2007;2139a. Marín Caro MM, Laviano A, Pichard C. Nutritional intervention and quality of life in adult oncology patients. Clin Nutr 2007 26(3):289–301. Hickman DM, Miller RA, Rombeau JL, Twomey PL, Frey CF. Serum albumin and body weight as predictors of postoperative course in colorectal cancer. JPEN J Parenter Enteral Nutr 1980;4:314–316. Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies ? Eur J Cancer 1998;34:503–509. Van Cutsem E, Arends J. The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs 2005;9:S51–S63. SFNEP (Société Francophone de Nutrition Entérale et Parentérale). Édition 2006. Circulaire DHOS/SDO/2005/101 du 22 février 2005 relative à l’organisation des soins en cancérologie. Mesure 40 du plan cancer. SROS III. CARMF BNC 2007 et évolution CREDES Charges professionnelles des médecins libéraux (2000). DRESS 2009 étude et résultats no 686 http: //www. sante. gouv. fr/drees/etude-resultat/doc.htm. Enquête SFED Deux jours d’endoscopie en France. au]http: //www. sfed. org/2-Jours-d-Endoscopie/ http: //www.carmf.fr/page.php?page=focus/Stats/2009/BNC.htm Analyse économique des coûts des cancers en France. Rapport INCa 2007. Boiteux (2001) Transports: choix des investissements et coûts des nuisances. Paris, Commissariat Général du Plan. Selke B, Durand I, Marissal JP, Chevalier D, Lebrun T. Coût du cancer colorectal en France en 1999. Gastroenterol Clin Biol 2003;27:22–27. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al Reducing mortality for colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365–1371. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467–1471 Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;34:1472–1477. Source PMSI. Berchi C, Bouvier V, Réaud JM, Launoy G. Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France. Health Economics 2004;13(3):227–238. Étude de cohorte Registre cancers digestifs Urcam Bourgogne A Bouvier et al. 2004. Rapport Institut de Veille Sanitaire 2009 http: //www.invs.sante.fr/publications/2009/plaq_eval_depistage_cancer_colon/plaq_eval_depistage_cancer_colon. pdf Eddy DM. Secondary prevention of cancer: an overview. Bull World Health Organ 1986;64:421–429. Cottet V, Pariente A, Nalet B, Lafon J, Milan C, Olschwang S, et al. Colonoscopy screening of first-degree relatives of patients with large adenomas: increased risk of colorectal tumors. Gastroenterology 200;133:1086–1092. Besoins nutritionnels. Cah Nutr Diét 36, hors série 1, 2001. Comment évaluer la qualité de l’ensemble du régime alimentaire ? Cah Nutr Diét 1999;34: 1. Ménat E. Dictionnaire pratique de la diététique. Éd. Jacques Granger. Recommandations de L’AFFSA. Bialek SR, Terrault NA. The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis 2006;10(4):697–715. Bronowicki JP, Barraud H, Peyrin-Biroulet L. Epidemiology and natural history of hepatitis C. Rev Prat 2005;55(6):607–614. Seeff LB. The natural history of chronic hepatitis C virus infection. Clin Liver Dis 1997;1(3):587–602. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004;24Suppl 2:3–8. Ascione A, Tartaglione T, Di Costanzo GG. Natural history of chronic hepatitis C virus infection. Dig Liver Dis 2007;39Suppl 1:S4–S7. Couzigou P, Mathurin P, Serfaty L, Cacoub P, Moussalli J, Pialoux G, et al. Alcohol, steatohepatitis, insulin resistance and hepatitis C. Gastroenterol Clin Biol 2008;32:S74–S81. Bhattacharya R, Shuhart MC. Hepatitis C and alcohol: interactions, outcomes, and implications. J Clin Gastroenterol 2003;36:242–252. HAS 2008 (in press). Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, Wedemeyer H, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009;16:75–90. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008;49(4):634–651. McHutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care 2005;11(10 Suppl):S286–S295. Freedman K, Nathanson J. Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders. Expert Rev Anti Infect Ther 2009;7(3):363–376. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother 2004;53(1):15–18. Epub 2003 Nov 25. Zeuzem S, Rizzetto M, Ferenci P, Shiffman ML. Management of hepatitis C virus genotype 2 or 3 infection: treatment optimization on the basis of virological response. Antivir Ther 2009;14(2):143–154. Ferenci P. Peginterferon and ribavirin in HCV: improvement of sustained viral response. Best Pract Res Clin Gastroenterol 2008;22(6):1109–1122. Berg T. Tailored treatment for hepatitis C. Clin Liver Dis 2008;12(3):507–528. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009;136(5):1618–1628. Zeuzem S, Nelson DR, Marcellin P. Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care ? Antivir Ther 2008;13(6):747–760. Mederacke I, Wedemeyer H, Manns MP. Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. Curr Opin Investig Drugs 2009;10(2):181–189. Gentile I, Viola C, Borgia F, Castaldo G, Borgia G. Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem 2009;16(9):1115–1121. Asselah T, Benhamou Y, Marcellin P. Protease and polymerase inhibitors for the treatment of hepatitis C. Liver Int 2009;29Suppl 1:57–67. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359(23):2429–2441. Ueno Y, Sollano JD, Farrell GC. Prevention of hepatocellular carcinoma complicating chronic hepatitis C. J Gastroenterol Hepatol 2009;24:531–536. But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008;14(11):1652–1656. Poynard T, Moussalli J, Ratziu V, Regimbeau C, Opolon P. Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma. Clin Liver Dis 1999;3(4):869–881. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50(2):227–242. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6(12):1315–1341. Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008;134(2):405–415. Perrillo RP, Jacobson IM. Halting the natural history of hepatitis B viral infection: a paradigm shift. Semin Liver Dis. 2007;27Suppl 1:3–8. Tenney, DJ M, et al. Données de résistance à six ans d’ETV (patient naïf et patient réfractaire à la lamivudine): 44th EASL, April 22–6, 2009, Copenhagen, Denmark. Oral 20. J Hepatol 2009;50(suppl 1) S10 Marcellin P, et al. AASLD 2008; Communications orales # 146 et 153. Brown R, et al. EASL 2009; Communication orale 3. Marcellin, et al. EASL 2009; Poster #925. Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, et al. Entecavir Therapy for Lamivudine-Refractory Chronic Hepatitis B: Improved Virologic, Biochemical, and Serology Outcomes Through 96 Weeks. Hepatology 2008;48:99–108. Reijnders JGP, et al. Effet antiviral de l’ETV dans le traitement de l’HCB: résultats d’une étude de cohorte internationale multicentrique (Virgil): 44th EASL, April 22–26, 2009, Copenhagen, Denmark. Oral 19. J Hepatol 2009;50(suppl. 1): S1 Leung N, et al. Traitement par ETV chez les patients non répondeurs ou résistants à l’Adéfovir. 44th EASL, April 22–6, 2009, Copenhagen, Denmark. Poster 919. J. Hepatol 2009;50(suppl. 1), S334. Berg et al. TDF vs TDF/FTC pour le traitement de l’HCB chez les patients ayant une réplication virale persistante sous traitement par ADV. 44th EASL April 22–6, Copenhagen, Denmark. Poster 903. J Hepatol 2009;50(suppl. 1): S328. Buti M, et al. EASL 2009; Communication orale 21. But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008;21;14(11):1652–1656. Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49(5 Suppl):S156–S165. Lau GK, Marcellin P, Brunetto M, Piratvisuth T, Kapprell HP, Button P, et al. On treatment HBsAg decline during peginterferon alfa-2a (40KD) +/- lamivudine in patients with HBe Ag-+ CHB as a potential predictor of durable off-treatment response of durable off-treatment response. EASL 2009, poster 910. Tan JJ, Tjandra JJ. Which is the optimal bowel preparation for colonoscopy — a meta-analysis. Colorectal Dis 2006;8(4:247–258. Shawki S, Wexner SD. Oral colorectal cleansing preparations in adults. Drugs 2008;68(4):417–437. Lichtenstein G. Bowel Preparation For Colonoscopy: A review. Am J Health Syst Pharm 2009;66(1):27–37. Nelson DB, Barkun AN, Block KP, Burdick JS, Ginsberg GG, Greenwald DA, et al. Technology Status Evaluation report. Colonoscopy preparations. May 2001. Gastrointest Endosc 2001;54:829–832. Lien YH. Is bowel preparation before colonoscopy a risky business for the kidney ? Nat Clin Pract Nephrol 2008;4(11):606–614. Buecher B, Bezieau S, Dufilhol C, Cauchin E, Heymann MF, Mosnier JF. Les polypes festonnés colorectaux: une entité revisitée. Gastroenterol Clin Biol 2007;31:39–54. Bretagne JF. Modalités de la surveillance endoscopique dans la prévention du cancer colique après polypectomie endoscopique et résection chirurgicale. Gastroenterol Clin Biol 2004;28:D178–D189. Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M, Italian Multicentre Study Group. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut 2001;48:812–815. Bertario L, Russo A, Sala P, Pizzetti P, Ballardini G, Andreola S, et al. Predictors of metachronous colorectal neoplasms in sporadic adenoma patients. Int J Cancer 2003;105:82–87. Jørgensen OD, Kronborg O, Fenger C, Rasmussen M. Influence of long-term colonoscopic surveillance on incidence of colorectal cancer and death from disease in patients with precursors. Acta Oncol 2007;46:355–360. Rosen DM, Sanchez NC, Whitlow CB, Beck DE, Hicks TC, Timmcke AE. Significant findings on screening colonoscopy. Dis Colon Rectum 2003;46:A51. Winawer SJ, Zauber AG, Ho MN, O’Brien MJ, Gottlieb LS, Sternberg SS, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329:1977–1981. Hixson LJ, Fennerty MB, Sampliner RE, McGee D, Garewal H. Prospective study of the frequency and size distribution of polyps missed by colonoscopy. J Natl Cancer Inst 1990;82:1769–1772. Rex DK, Cutler CS, Lemmel GT, Rahmani EY, Clark DW, Helper DJ, et al. Colonoscopic miss rates of adenomas determined by back to back colonoscopy. Gastroenterology 1997;112:24–28. Bensen S, Mott LA, Dain B, Rothstein R, Baron J. The colonoscopy miss rate and true on year recurrence of colorectal neoplastic polyps. Am J gastroenterol 1999;94:194–199. Postic G, Lewin D, Bickerstaff C, Wallace MB. Colonoscopic miss rates determined by direct comparison of colonoscopy with colon resection specimens. Am J Gastroenterol 2002;97:3182–3185. Imperiale TF, Glowinski EA, Juliar BE, Azzouz F, Ransohoff DF. Variation in polyp detection rates at screening colonoscopy. Gastrointest Endosc. 2009;69(7):1288–1295. Konishi K, Kaneko K, Kurahashi T, Yamamoto T, Kushima M, Kanda A, et al. A comparaison of magnifying and non magnyfying colonoscopy for diagnosis of colorectal polyps: a prospective study. Gastrointest endosc 2003;57:48–53. Nelson DB, McQuaid KR, Bond JH, Lieberman DA, Weiss DG, Johnston TK. Procedural success and complications of largescale screening colonoscopy. Gastrointest Endosc 2002;55:307–314. Meining A, Morgner A, Miehlke S, Bayerdörffer E, Stolte M. Atrophy-metaplasia-dysplasia-carcinoma sequence in the stomach: a reality or merely an hypothesis ? Best Pract Res Clin Gastroenterol 2001;15:983–998. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the developement of gastric cancer. N Engl J Med 2001;345:784–789. Shimizu N, Ikehara Y, Inada K, Nakanishi H, Tsukamoto T, Nozaki K, et al. Eradication diminishes enhancing effects of Helicobacter pylori-infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Res 2000;60:1512–1514. Keto Y, Ebata M, Okabe S. Gastric mucosal changes induced by long-term infection with Helicobacter pylori in Mongolian gerbils: effects of bacteria eradication. J Physiol Paris 2001;95:429–436. Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxydant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881–1888. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a high risk region in china: A randomized controlled trial. JAMA 2004;291:187–194. Dubuc J, Legoux JL, Winnock M, Seyrig JA, Barbier JP, Barrioz T, et al. Endoscopic screening for squamous cell carcinoma in high risk patients: a prospective study conducted in 62 French endoscopy centers. Endoscopy 2006;38:690–695. Malferheiner P, Megraud F, O’Morain, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of helicobacter pylori infection: the Maastricht III consensus report. Gut 2007;56:772–781. Chey WD, Wong BCY. American College of Gastroenterology guideline on management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808–1825. Khakoo SI, Lobo AJ, Shepherd NA, Wilkinson SP. Histological assesment of the sydney classification of endoscopic gastritis. Gut 1994;35:1172–1175. Genta RM, Graham DY. Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of helicobacter density and distribution. Gastrointest Endosc 1994;40:342–345. Dixon M, Genta R, Yardley J, Correa P. Classification and grading of gastritis: the updated Sydney System. Am J Surg Pathol 1996;20:1161–1181. Uemera N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784–789. Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, et al. Effect of helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997;6:639–642. Leung WK, Lin SR, Ching JY, To KF, Ng EK, Chan FK, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomized trial on Helicobacter pylori eradication. Gut 2004;53:1244–1249. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187–194. Lamouliatte H, Mégraud F, Delchier JC, Bretagne JF, Courillon-Mallet A, De Korwin JD, et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 2003;18:791–797. Borody TJ, Pang G, Wettstein AR, Clancy R, Herdman K, Surace R, et al. Efficacy and safety of rifabutin-containing ‘rescue therapy’ for resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006;23:481–488. Gisbert JP, Bermejo F, Castro-Fernández M, Pérez-Aisa A, Fernández-Bermejo M, Tomas A, et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: A Spanish multicenter study of 300 patients. Am J Gastroenterol 2008;103:71–76. Kabir S. The current status of Helicobacter pylori Vaccines: A review. Helicobacter 2007;12:89–102. Canard JM, Debette-Gratien M, Dumas R, Escourrou J, Gay G, Giovannini M, et al. A prospective national study on colonoscopy and sigmoidoscopy in 2000 in France. Gastroenterol Clin Biol 2005;29:17–22. Pienkowski P, Houcke Ph, Lledo G, Richard-Molard B, Rouillon JM, Hubert C. Observatoire du Cancer Colorectal: Résultats d’une enquête nationale de pratique en milieu libéral. Acta Endoscopica 2007;37:131–148 L Bedenne et al. Pratique de la cancérologie digestive par les hépatogastroentérologues: évolutions de 2000 à 2008 à travers des enquêtes nationales FSMAD-FFCD. Gastroenterol Clin Biol, 2009;33:A164. Thésaurus National de Cancérologie Digestive. Société Nationale Française de Gastroentérologie. http: //www.tncd.org. Référentiels de bon usage hors GHS. Protocoles thérapeutiques hors GHS. Cancers digestifs. INCa, HAS et Affsaps. Mai 2009. Arnott SJ, Duncan W, Gignoux M, Girling DJ, Hansen HS, Launois B, et al. Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group). Int J Radiat Oncol Biol Phys 1998;41:579–583. Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, et al. Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102). J Clin Oncol 2007;25:1160–1168. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593–1598. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for respectable gastroesophageal cancer. N Engl J Med 2006;355:11–20. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and Oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36–46. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007–1016. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and Chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408–1417. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin and oxaliplatin with and without Cetuximab in the first-line treatment of Metastatic Colorectal Cancer. J Clin Oncol 2009;27:663–671. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer — a GERCOR study. J Clin Oncol 2006;24:394–400. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of Chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200–1210. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267–277. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med 2008;359:378–390. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70(3):439–444 Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn’s disease. A prospective multicentre study of 121 cases. The Groupe d’Études Thérapeutiques des Affections Inflammatoires Digestives. Gut 1994;35(2):231–235 Harvey RF, Bradshaw MJ. Measuring Crohn’s disease activity. Lancet 1980;1:1134–1135 Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989;30(7):983–989 Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99(4):956–963. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82–86. D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763–786 Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041–1048. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330(26):1841–1845. Lemann M. Scores endoscopiques dans les maladies inflammatoires chroniques de l’intestin, intérêts pratiques. FMC Gastr 2002; Post U. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, et al Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 2006;63:433–442. Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412–422. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn’s disease. Gastroenterology 2006;130:650–656. Seksik P, Loftus EV, Beaugerie L, Harmsen WS, Zinsmeister AR, Cosnes J, et al. Validation of predictors of 5-years disabling CD in a population based cohort from Olstead County Minnesota 1983–1996 Gastroenterology 2007;132(Suppl 2):A17. Tramm A, et al. AGA 2009 Gastroenterology. 2009;139(suppl 1)391. Doherty GA, et al. AGA 2009 Gastroenterology. 2009;136(suppl 1)1210. Sandborn WJ. Current directions in IBD thérapy: what goals are feasible with biological modifiers ? Gastroenterology 2008;135:1442–1447. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodmann R. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995;37:674–678. Hanauer SB, Sandborn W. Management of Crohn’s disease in adults. Am J Gastroenterol 2001;96:635–643. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med 1995;332:292–297 Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, Macintosh D, et al Human anti-tumor necrosis factor monoclinac antibody(adalimumab) in Crohn’s disease: the CLASSIC trial. Gastroenterology 2006;130:323–333. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease. The ACCENT 1 randomised trial. Lancet 2002;359:1541–1549. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panacione R, et al. Adalimumab for maintenance of clinical response and rémission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007;132 52–65. Sandborn WJ, Rutgeerts P, reinisch W, Gerassimos J, Mantzaris GJ, Kornbluth A, Rachmilewitz D et al. One year data from the sonic study; Digestive Disease Week (DDW), 2009. Louis E, Vernier-Massouille G, Grimaud j, et al. Infliximab discontinuation in Crohn’s disease patients in stable remission on combined therapy with immunosuppressors: interim analysis of a prospective cohort study. United European Gastroenterology Week (UEGW), 2008. Toruner M, Loftus Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929–936. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M,. Hepatosplenic T cell lymphoma associated with infleximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265–267. Chauvenet M, Libeskind M. Intérêt de la diosmine d’hémisynthèse dans la poussée hémorroïdaire aigüe. Essai multicentrique randomisé en double insu, versus placebo. Rev Fr Gastroenterol 1994;30:642 Cospite M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorroids. Angiology 1994;45:566–573. Debien P, Denis J. Traitement des signes fonctionnels de la crise hémorroïdaire aigüe: Essai multicentrique, randomisé, diosmine d’hémisynthèse versus association extrait de Ginkgo biloba-heptaminol-troxérutine. Med Chir Dig 1996;25:255–255 MacRae HM, McLeod RS. Comparison of hemorrhoidal treatment modalities. A meta-analysis. Dis Colon Rectum 1995;38:687–694. Faucheron J. -L., Gangner Y. Doppler-guided hemorrhoidal artery ligation for the treatment of symptomatic hemorrhoids: early and three-year follow-up results in 100 consecutive patients. Dis Colon Rectum 2008;51(6):945–949. Ramirez JM, Aguilella V, Elia M, Garcia JA, Martinez M. Doppler-guided hemorrhoidal artery ligation in the management of symptomatic hemorrhoids. Rev Esp Enferm Dig 2005;97:97–103. Scheyer M, Antonietti E, Rollinger G, Mall H, Arnold S. Doppler-guided hemorrhoidal artery ligation. Am J Surg 2006;191:89–93. Murie JA, Mackenzie I, Sim AJ. Comparison of rubber band ligation and haemorrhoidectomy for second and third degree hemorrhoids: a prospective clinical trial. Br J Surg 1980;67:786–788. Nisar PJ, Acheson AG, Neal KR, Scholefield JH. Stapled hemorrhoidopexy compared with conventional hemorrhoidectomy: systematic review of randomized, controlled trials. Dis Colon Rectum 2004;47:1837–1845. Ortiz H, Marzo J, Armendáriz P, De Miguel M. Stapled hemorroidopexy vs diathermy excision for fourth-degree hemorrhoids: a randomized, clinical trial and review of the literature. Dis Colon Rectum 2005;48:809–815. Johanson JF, Rimm A. Optimal nonsurgical treatment of hemorrhoids: a comparative analysis of infrared coagulation, rubber band ligation, and injection sclerotherapy. Am J Gastroenterol 1992;87(11):1600–1606. Spira A, Bajos et le groupe ACSF. Les comportements sexuels en France. Paris: la Documentation Française, 1993 (352 p.). Enquête sur la sexualité des français, avril 2009, tns-sofres.co Les femmes et la sexualité, sondage IFOP, Elle, 8 mai 2006. Jay K, Young A. The Gay Report: lesbian and gay men speak about their sexual experiences and lifestyles. New York: Summit, 1977. Chun AB, Rose S, Mitrani C, Silvestre AJ, Wald A. Anal sphincter structure and function in homosexual males engaging in anoreceptive intercourse. Am J Gastroenterol 1997;92(3):465–468. Rosser BR, Short BJ, Thurmes PJ, Coleman E. Anodyspareunia, the unacknowledged sexual dysfunction: a validation study of painful receptive anal intercourse and its psychosexual concomitants in homosexual men. J Sex Marital Ther 1998;24(4):281–292. Engel AF, Kamm MA, Bartram CI. Unwanted anal penetration as a physical cause of faecal incontinence. Eur J Gastroenterol Hepatol 1995;7(1):65–67. Rakotomalala L, de Parades V, Parisot C, Atienza P. Ruptures multiples du sphincter interne après viol anal. Gastroenterol Clin Biol 1996;20(12):1142–1143. Chen YM, Davis M, Ott DJ. Traumatic rectal hematoma following anal rape. Ann Emerg Med 1986;15(7):850–852. Drossman DA. Irritable bowel syndrome and sexual/physical abuse history. Eur J Gastroenterol Hepatol 1997;9(4):327–330. du Puy Montbrun T. Proctologie et violence sexuelle: du mythe à la réalité. Hepato-Gastro 2008;15(3):207–213. Nehme Kingsley A, Abcarian H. Colorectal foreign bodies management update. Dis Colon Rectum 1985;28(12):941–944. Witz M, Shpitz B, Zager M, Eliashiv A, Dinbar A. Anal erotic instrumentation. A surgical problem. Dis Colon Rectum 1984;27(5):331–332. Agnew J. Klismaphilia, a physiological perspective. Am J Psychother 1982;36:554–566. Anonymous. Female condom use by men. Posit Aware 1998;9(5):23. Frisch M, Glimelius B, van den Brule AJ, Wohlfahrt J, Meijer CJ, Walboomers JM, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med 1997;337:1350–1358.